Home›Companies›Biotech & Pharma›Optimeos

Optimeos Life Sciences, Inc.

Develops drug delivery technologies for companies working on gene therapies and other medicines.

Updated Nov 12, 2026·Latest SEC filing Jun 3, 2026·Suggest an edit

About Optimeos

Optimeos is a private company based in Princeton, New Jersey. It has reported $4,369,996 raised in four offerings on Form D since August 2020. Its chief executive is Shahram Hejazi.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
May 22, 2026Jun 3, 2026$1,000,000of $2.0M target1$1.0MDebt, OptionsRule 506(b)Form D ↗
Jun 26, 2023Jul 7, 2023amended Nov 26, 2024$2,924,996of $5.0M target5$584KEquity, Equity to be issued upon conversion of previously issued convertible securitiesRule 506(b)Form D/A ↗1 earlier filing
May 17, 2021Jun 1, 2021$175,000of $300K target4$43,750Debt, Options, Securities on exerciseRule 506(b)Form D ↗
Aug 6, 2020Aug 7, 2020$270,000of $400K target3$90,000Debt, Options, Securities on exerciseRule 506(b)Form D ↗
Total, four offerings$4,369,996

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Optimeos's Form D filed Jun 3, 2026.

JS
Jason Smith
Head of Business Development and director
SH
Shahram Hejazi
Founding CEO and director
RH
Robert Prud'homme
Co-founder and Chief Technical Officer, director
BD

Sources

  1. SECOptimeos Life Sciences, Inc. Form D, filed Jul 7, 2023
  2. SECOptimeos Life Sciences, Inc. filing history
  3. PressIntegral Molecular and Optimeos partnership